Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval · Investor's Business Daily

In This Article:

Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.